URA is pleased to announce the following funding opportunities specific to COVID-19. This list will be updated as new opportunities arise.
NSF: https://www.nsf.gov/pubs/2020/nsf20052/nsf20052.jsp
NSF encourages the research community to respond to the COVID-19 challenge through existing funding opportunities. In addition, we invite researchers to use the Rapid Response Research (RAPID) funding mechanism, which allows NSF to receive and review proposals having a severe urgency with regard to availability of or access to data, facilities or specialized equipment as well as quick-response research on natural or anthropogenic disasters and similar unanticipated events. Requests for RAPID proposals may be for up to $200K and up to one year in duration. Well-justified proposals that exceed these limits may be entertained.
NIH: https://www.niaid.nih.gov/grants-contracts/response-covid-2019-outbreak
If you are a grantee currently supported by active NIH funding, you may be eligible to apply for an administrative supplement to support SARS-CoV-2/COVID-2019 research. Contact your program officer to discuss if this may be an option for you. If your proposed research on SARS-CoV-2/COVID-2019 is within the scope of your current grant, an administrative supplement is your best option to obtain additional funding. You’ll apply using the parent administrative supplement funding opportunity announcement (FOA): PA-18-591
In response to the COVID-2019 outbreak caused by SARS-CoV-2, NIAID, together with the National Institute of General Medical Sciences (NIGMS), is using the NIH Urgent Award mechanism for the first time. The corresponding Notice of Special Interest (NOSI) Regarding the Availability of Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus (SARS-CoV-2) highlights the urgent need for research on SARS-CoV-2.
Health and Human Services (HHS) Office of Biomedical Advanced Research and Development Authority (BARDA): https://beta.sam.gov/opp/1b46a4169fcb4902b9c4fcbb5bf981f7/view
HHS BARDA has revised its Broad Agency Announcement (BAA) to only accept proposals and white papers in areas relevant to the study of COVID-19. Areas of interest include:
- AOI 7.7.1 Diagnostic assay for human coronavirus using existing FDA-cleared platforms
- AOI 7.7.2 Point-of-care diagnostic assay for detection of SARS-CoV-2 virus
- AOI 7.7.3 Diagnostic assay for detection of COVID-19 disease (SARS-CoV-2 infection)
- AOI 8.3 COVID-19 Vaccine
- AOI 9.2 COVID-19 Therapeutics
- AOI 9.3 Immunomodulators or therapeutics targeting lung repair
- AOI 9.5 Pre-exposure and post-exposure prophylaxis
- AOI 10 Respiratory protective devices
- AOI 11 Ventilators
- AOI 17 Advanced Manufacturing Technologies
Gates Foundation: https://www.gatesfoundation.org/Media-Center/Press-Releases/2020/03/COVID-19-Therapeutics-Accelerator
The Bill & Melinda Gates Foundation, Wellcome, and Mastercard committed up to $125 million in seed funding to speed-up the response to the COVID-19 epidemic by identifying, assessing, developing, and scaling-up treatments. The COVID-19 Therapeutics Accelerator will play a catalytic role by accelerating and evaluating new and repurposed drugs and biologics to treat patients with COVID-19 in the immediate term, and other viral pathogens in the longer-term. By providing fast and flexible funding at key stages of the development process, the Accelerator will de-risk the pathway for new drugs and biologics for COVID-19 and future epidemic threats, ensuring access in lower-resource countries.
Cross Reference with UC Research Continuity Planning for COVID-19 page:
COVID-19 Research Related Resources